With their diverse biological effects, GLP-1 therapies are emerging as powerful tools not just for metabolic health but also for promoting longevity and overall wellness
Optum will add Wegovy to the PF, requiring plans to cover the drug for cardiovascular risk reduction in a select population, which will most likely increase plan spend
That may include weight loss, improved insulin sensitivity, reduced visceral fat, better cardiometabolic markers, lower inflammatory burden, improved mobility, and greater capacity to exercise
500 mg of pure glutathione and activated B vitamin cofactors delivered in phosphatidylcholine liposomes for optimal absorption and bioavailability support
1b, c), and plasma lipid profile (Table 3)